Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867988 | 0.87 | EPHX2 (0.65) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL16912996 | 0.87 | EPHX2 (0.63) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL23362073 | 0.84 | MAPT (0.70) | EPHX2ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL1869601 | 0.84 | PKM (0.70) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL1866862 | 0.84 | EPHX2 (0.61) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL854322 | 0.84 | SMN1; SMN2 (0.63) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL16912986 | 0.82 | SMN1; SMN2 (0.64) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL2285784 | 0.82 | ALDH1A1 (0.76) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL7133340 | 0.81 | SMN1; SMN2 (0.60) | EPHX2ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL1519692 | 0.81 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2LMNAHTTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | EPHX2 2046/4885ALDH1A1 3161/4885SMN1; SMN2 216/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | EPHX2 3029/4885ALDH1A1 796/4885SMN1; SMN2 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.